Would you consider 177Lu-PSMA-617 for a patient with mCRPC that has neuroendocrine features on biopsy but PSMA-positive disease on PET?
Answer from: Medical Oncologist at Academic Institution
That depends somewhat on the extent of PSMA positive disease. mCRPC is a heterogeneous disease - if the majority of the disease is clearly PSMA positive, then I think it would be reasonable to use PSMA-directed therapy regardless of what the biopsy is demonstrating.
Comments
Medical Oncologist at Rutgers Cancer Institute of New Jersey More important than the biopsy would be functional...
Medical Oncologist at Duke University School of Medicine Agreed. PSMA positivity of lesions (brighter the b...
More important than the biopsy would be functional...
Agreed. PSMA positivity of lesions (brighter the b...